FDA’s Sachdev resigns
This article was originally published in The Tan Sheet
Executive Summary
Deputy Commissioner for Policy Amit Sachdev formally resigns from the agency, Acting Commissioner Lester Crawford announces in an internal memorandum. Crawford cited Sachdev's work with Congress on FDA oversight, his contributions to expanding the agency's access to more resources for its various centers and leadership in speeding up review of medicines to treat HIV/AIDS under the White House's global AIDS initiative. Sachdev, whose last day was March 25, has not disclosed his future plans...
You may also be interested in...
FDA Commissioner Confirmation Clears The Way For Personnel Changes
The confirmation of FDA Commissioner Lester Crawford will allow for a reorganization of upper level management at the agency
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.